Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial

Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and intermediate-fit MM patients during active treatment and post-treatment follow-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 2024-08, Vol.207, p.114153, Article 114153
Hauptverfasser:	Seefat, M.R., Stege, C.A.M., Lissenberg-Witte, B.I., Levin, M.D., Timmers, G.J., Hoogendoorn, M., Ypma, P.F., Klein, S.K., Velders, G.A., Westerman, M., Strobbe, L., Durdu-Rayman, N., Davidis-van Schoonhoven, M.A., van Kampen, R.J.W., Dijk, A.C., Koster, A., Silbermann, M.H., van der Spek, E., Beeker, A., Erjavec, Z., de Graauw, N.C.H.P., Leys, M.B.L., Sonneveld, P., van de Donk, N.W.C.J., Nasserinejad, K., Blommestein, H.M., Cucchi, D.G.J., Zweegman, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Frailty score IMWG Multiple myeloma Newly diagnosed Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!